Cwm LLC grew its stake in shares of Lam Research Corporation (NASDAQ:LRCX – Free Report) by 2.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,491 shares of the semiconductor company’s stock after acquiring an additional 1,368 shares during the period. Cwm LLC’s holdings in Lam Research were worth $6,570,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in LRCX. Brighton Jones LLC increased its holdings in shares of Lam Research by 1,032.4% during the fourth quarter. Brighton Jones LLC now owns 14,189 shares of the semiconductor company’s stock worth $1,025,000 after purchasing an additional 12,936 shares during the period. GAMMA Investing LLC increased its holdings in shares of Lam Research by 21.5% during the first quarter. GAMMA Investing LLC now owns 29,408 shares of the semiconductor company’s stock worth $2,138,000 after purchasing an additional 5,213 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Lam Research by 14.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 300,193 shares of the semiconductor company’s stock worth $21,824,000 after purchasing an additional 36,825 shares during the period. Dynamic Advisor Solutions LLC increased its holdings in shares of Lam Research by 8.8% during the first quarter. Dynamic Advisor Solutions LLC now owns 14,308 shares of the semiconductor company’s stock worth $1,040,000 after purchasing an additional 1,161 shares during the period. Finally, Sowell Financial Services LLC increased its holdings in shares of Lam Research by 4.7% during the first quarter. Sowell Financial Services LLC now owns 20,047 shares of the semiconductor company’s stock worth $1,457,000 after purchasing an additional 899 shares during the period. 84.61% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research analysts have recently commented on LRCX shares. Hsbc Global Res raised shares of Lam Research to a “hold” rating in a report on Tuesday, September 30th. Morgan Stanley set a $125.00 price objective on shares of Lam Research and gave the company an “equal weight” rating in a research note on Monday, September 22nd. Cantor Fitzgerald lifted their price objective on shares of Lam Research from $155.00 to $170.00 and gave the company an “overweight” rating in a research note on Tuesday. Raymond James Financial lifted their price objective on shares of Lam Research from $90.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, July 31st. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Lam Research in a research note on Wednesday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $123.80.
Lam Research Stock Performance
Shares of Lam Research stock opened at $144.78 on Thursday. Lam Research Corporation has a fifty-two week low of $56.32 and a fifty-two week high of $153.70. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.21 and a quick ratio of 1.55. The firm has a market capitalization of $182.57 billion, a P/E ratio of 34.80, a P/E/G ratio of 1.68 and a beta of 1.84. The company’s 50 day moving average price is $117.40 and its two-hundred day moving average price is $95.82.
Lam Research (NASDAQ:LRCX – Get Free Report) last issued its earnings results on Wednesday, July 30th. The semiconductor company reported $1.33 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.12. Lam Research had a net margin of 29.07% and a return on equity of 58.17%. The firm had revenue of $5.17 billion for the quarter, compared to analyst estimates of $4.99 billion. During the same quarter last year, the business posted $1.03 earnings per share. The company’s quarterly revenue was up 33.6% on a year-over-year basis. Lam Research has set its Q1 2026 guidance at 1.100-1.300 EPS. On average, equities analysts forecast that Lam Research Corporation will post 3.71 earnings per share for the current fiscal year.
Lam Research Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Wednesday, October 15th. Shareholders of record on Wednesday, September 24th were given a $0.26 dividend. This is an increase from Lam Research’s previous quarterly dividend of $0.23. This represents a $1.04 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Wednesday, September 24th. Lam Research’s dividend payout ratio (DPR) is 25.00%.
Insiders Place Their Bets
In other Lam Research news, SVP Vahid Vahedi sold 52,190 shares of the firm’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $138.90, for a total value of $7,249,191.00. Following the sale, the senior vice president owned 251,047 shares in the company, valued at $34,870,428.30. This trade represents a 17.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.31% of the stock is owned by corporate insiders.
Lam Research Company Profile
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.
Read More
- Five stocks we like better than Lam Research
- What is the Australian Securities Exchange (ASX)
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Best Aerospace Stocks Investing
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Investing In Automotive Stocks
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Lam Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lam Research and related companies with MarketBeat.com's FREE daily email newsletter.